Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 19/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169236 | 0.89 | ALOX5AP (0.66) | ALOX5APPTGS1 | |
| SCHEMBL1253718 | 0.85 | ALOX5AP (0.68) | ALOX5APCYP2C9PTGS1 | |
| SCHEMBL12014953 | 0.85 | PTGES2 (0.57) | ALOX5APCYP3A4CYP2C9PTGS1PTGES2 | |
| SCHEMBL167199 | 0.84 | PTGES2 (0.66) | ALOX5APCYP3A4CYP2C9PTGES2 | |
| SCHEMBL13886900 | 0.84 | ALOX5AP (0.65) | ALOX5APCYP3A4CYP2C9PTGS1 | |
| SCHEMBL176187 | 0.84 | PTGES2 (0.56) | ALOX5APCYP3A4CYP2C9PTGS1PTGES2 | |
| SCHEMBL10264786 | 0.84 | PTGES2 (0.56) | ALOX5APCYP3A4CYP2C9PTGS1PTGES2 | |
| SCHEMBL13415379 | 0.82 | ALOX5AP (0.68) | ALOX5APPTGS1 | |
| SCHEMBL1193618 | 0.81 | ALOX5AP (0.67) | ALOX5APCYP3A4CYP2C9PTGS1 | |
| SCHEMBL1193620 | 0.81 | ALOX5AP (0.67) | ALOX5APCYP3A4CYP2C9PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068301-A1 | COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS | PANMIRA PHARMACEUTICALS, LLC | 2010-03-18 | — | — | US | disclosed |
| US-20100068301-A1 | COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS | PANMIRA PHARMACEUTICALS, LLC | 2010-03-18 | — | — | US | disclosed |
| EP-2086531-A1 | COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS | Amira Pharmaceuticals, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008067566-A1 | COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068301-A1 | COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS | ALOX5, ALOX15B, PTGIS | ALOX5AP 5/4885CYP3A4 1011/4885CYP2C9 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.